BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -81.80% | -60.92% | -42.18% | -24.29% | -7.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.80% | -60.92% | -42.18% | -24.29% | -7.04% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -81.80% | -60.92% | -42.18% | -24.29% | -7.04% |
| SG&A Expenses | -24.73% | -33.66% | -18.70% | -25.18% | -11.51% |
| Depreciation & Amortization | -12.44% | -2.99% | 95.98% | 44.15% | 22.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.46% | -18.65% | -2.84% | -17.45% | -4.97% |
| Operating Income | 3.37% | 15.47% | -0.34% | 16.91% | 4.78% |
| Income Before Tax | 16.54% | 23.14% | 12.21% | 18.16% | -2.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.54% | 23.14% | 12.21% | 18.16% | -2.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.54% | 23.14% | 12.21% | 18.16% | -2.80% |
| EBIT | 3.37% | 15.47% | -0.34% | 16.91% | 4.78% |
| EBITDA | 3.45% | 15.63% | -0.32% | 17.09% | 4.90% |
| EPS Basic | 5.77% | 18.40% | 11.45% | 42.94% | 24.64% |
| Normalized Basic EPS | 6.15% | 17.95% | 12.20% | 43.14% | 24.42% |
| EPS Diluted | 5.77% | 18.40% | 11.45% | 42.94% | 24.64% |
| Normalized Diluted EPS | 6.15% | 17.95% | 12.20% | 43.14% | 24.42% |
| Average Basic Shares Outstanding | -64.46% | -64.14% | -63.52% | 240.81% | 244.21% |
| Average Diluted Shares Outstanding | -64.46% | -64.14% | -63.52% | 240.81% | 244.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |